LINC 2023: Late-breaking Science Video Collection
Published: 20 June 2023
-
Views:
794
-
Likes:
7
-
Views:
794
-
Likes:
7
-
Up Next -
4m 48sPart 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date -
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes -
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease -
3m 49sPart 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions -
6m 6sPart 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK -
8m 56sPart 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola
-
5m 18sPart 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups Marianne Brodmann
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
About the episode
LINC 23 - Dr Marianne Brodmann (Medical University of Graz, AT) joins us to discuss the findings from the RANGER II SFA Trial, originally presented at LINC's 2023 scientific sessions. The RANGER trial set out to evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon in treating lesions in the superficial femoral and proximal popliteal arteries. This trial enrolled a cohort of 440 patients.
In this interview, Dr Brodmann reveals the long-term efficacy results. These suggested that the Ranger device had an efficient outcome in regard to target lesion revascularisation at both 3 and 4 years.
Interview Questions:
- Tell us about the device investigated in this trial and its unique features.
- What was the patient cohort and study design?
- What are the key findings revealed at LINC 23?
- Are there any patient groups that could benefit more from the use of this DCB?
- What further research is still required?
- What are the next steps?
Recorded remotely from Graz, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Faculty Biographies
Marianne Brodmann
Professor, Head of the Clinical Division of Angiology
Dr Marianne Brodmann is the Head of Division of Angiology, Head of Clinical Research at Division of Angiology at the Medical University of Graz, Austria.
Dr Brodmann is a Fellow of the European Society of Cardiology, Board Member of the European Union of Medical Specialist (UEMS), past President of the ÖGA (Austrian Society of Angiology) and National Delegate of the IUA (International Union of Angiology).
Research activities include anticoagulation and thrombolysis, new endovascular technologies in the peripheral field and evaluation of the nature of restenosis. She also founded a research establishment for experimental angiology animal models at the University of Graz.
Dr Brodmann has participated in over 50 international clinical trials including Principal Investigator for the Bioflex I, Lutonix BTK and TOBA-BTK clinical trials and Steering Committee of the CVI Ingenuity trial.
Comments